Abstract
As diverse therapeutic options are now available for advanced melanoma patients, predictive markers that may assist treatment decision are needed. A model based on baseline serum lactate dehydrogenase (LDH), peripheral blood relative lymphocyte counts (RLC) and eosinophil counts (REC) and pattern of distant metastasis, has been recently proposed for pembrolizumab-treated patients. Here, we applied this model to advanced melanoma patients receiving chemotherapy (n = 116) or anti- CTLA-4 therapy (n = 128). Visceral involvement, LDH and RLC were associated with prognosis regardless of treatment. Instead, when compared to chemotherapy-treated patients with REC < 1.5%, those with REC ≥ 1.5% had improved overall survival when receiving anti-CTLA-4 [Hazard Ratio (HR) = 0.56 (0.4-0.93)] but not chemotherapy [HR = 1.13, (0.74-1.74)], and the treatment-by-REC interaction was significant for both overall (p = 0.04) and progression free survival (p = 0.009). These results indicate baseline REC ≥ 1.5% as a candidate predictive biomarker for benefit from anti-CTLA-4. Further studies are needed to confirm these findings in patients receiving immune-modulating agents.
| Original language | English |
|---|---|
| Pages (from-to) | 79809-79815 |
| Number of pages | 7 |
| Journal | Oncotarget |
| Volume | 8 |
| Issue number | 45 |
| DOIs | |
| Publication status | Published - Jan 1 2017 |
Fingerprint
Keywords
- Biomarker
- Eosinophil
- Ipilimumab
- Melanoma
- Predictive
ASJC Scopus subject areas
- Oncology
Cite this
Baseline relative eosinophil count as a predictive biomarker for ipilimumab treatment in advanced melanoma. / Ferrucci, Pier Francesco; Gandini, Sara; Cocorocchio, Emilia; Pala, Laura; Baldini, Federica; Mosconi, Massimo; Cappellini, Gian Carlo Antonini; Albertazzi, Elena; Martinoli, Chiara.
In: Oncotarget, Vol. 8, No. 45, 01.01.2017, p. 79809-79815.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Baseline relative eosinophil count as a predictive biomarker for ipilimumab treatment in advanced melanoma
AU - Ferrucci, Pier Francesco
AU - Gandini, Sara
AU - Cocorocchio, Emilia
AU - Pala, Laura
AU - Baldini, Federica
AU - Mosconi, Massimo
AU - Cappellini, Gian Carlo Antonini
AU - Albertazzi, Elena
AU - Martinoli, Chiara
PY - 2017/1/1
Y1 - 2017/1/1
N2 - As diverse therapeutic options are now available for advanced melanoma patients, predictive markers that may assist treatment decision are needed. A model based on baseline serum lactate dehydrogenase (LDH), peripheral blood relative lymphocyte counts (RLC) and eosinophil counts (REC) and pattern of distant metastasis, has been recently proposed for pembrolizumab-treated patients. Here, we applied this model to advanced melanoma patients receiving chemotherapy (n = 116) or anti- CTLA-4 therapy (n = 128). Visceral involvement, LDH and RLC were associated with prognosis regardless of treatment. Instead, when compared to chemotherapy-treated patients with REC < 1.5%, those with REC ≥ 1.5% had improved overall survival when receiving anti-CTLA-4 [Hazard Ratio (HR) = 0.56 (0.4-0.93)] but not chemotherapy [HR = 1.13, (0.74-1.74)], and the treatment-by-REC interaction was significant for both overall (p = 0.04) and progression free survival (p = 0.009). These results indicate baseline REC ≥ 1.5% as a candidate predictive biomarker for benefit from anti-CTLA-4. Further studies are needed to confirm these findings in patients receiving immune-modulating agents.
AB - As diverse therapeutic options are now available for advanced melanoma patients, predictive markers that may assist treatment decision are needed. A model based on baseline serum lactate dehydrogenase (LDH), peripheral blood relative lymphocyte counts (RLC) and eosinophil counts (REC) and pattern of distant metastasis, has been recently proposed for pembrolizumab-treated patients. Here, we applied this model to advanced melanoma patients receiving chemotherapy (n = 116) or anti- CTLA-4 therapy (n = 128). Visceral involvement, LDH and RLC were associated with prognosis regardless of treatment. Instead, when compared to chemotherapy-treated patients with REC < 1.5%, those with REC ≥ 1.5% had improved overall survival when receiving anti-CTLA-4 [Hazard Ratio (HR) = 0.56 (0.4-0.93)] but not chemotherapy [HR = 1.13, (0.74-1.74)], and the treatment-by-REC interaction was significant for both overall (p = 0.04) and progression free survival (p = 0.009). These results indicate baseline REC ≥ 1.5% as a candidate predictive biomarker for benefit from anti-CTLA-4. Further studies are needed to confirm these findings in patients receiving immune-modulating agents.
KW - Biomarker
KW - Eosinophil
KW - Ipilimumab
KW - Melanoma
KW - Predictive
UR - http://www.scopus.com/inward/record.url?scp=85030472711&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85030472711&partnerID=8YFLogxK
U2 - 10.18632/oncotarget.19748
DO - 10.18632/oncotarget.19748
M3 - Article
AN - SCOPUS:85030472711
VL - 8
SP - 79809
EP - 79815
JO - Oncotarget
JF - Oncotarget
SN - 1949-2553
IS - 45
ER -